Pharsight

1. List of Talzenna drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420650	PFIZER	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)	Jul, 2029 (6 years from now)
US8012976	PFIZER	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)	Oct, 2029 (6 years from now)
US10189837	PFIZER	Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt	Oct, 2031 (8 years from now)
US8735392	PFIZER	Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt	Oct, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820985	PFIZER	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)	Jul, 2029 (6 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 16, 2023

NCE-1 date: 2022-10-16

Market Authorisation Date: 16 October, 2018

Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locall...

Dosage: CAPSULE;ORAL